Iijima Masami's Form 4 filing
Takeda Pharmaceutical Co Ltd (TAK) · filed Jul 6, 2026
- Accession no.
- 0001395064-26-000270
- Filed
- Jul 6, 2026, 6:14 PM ET
- Trade date
- Jul 1-10, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Iijima MasamiCIK 0002114485 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Ordinary Shares | AGrant or awardAcquired | +1,800 | $0.00 | $0 | 14,601 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Ordinary Shares | DReturned to the companyDisposed | −2,152 | JPY 4,931.20F3Price in JPY, as filed | −JPY 10,611,942.4 | 0 | Direct | Price outlier |
| Jul 1, 2026 | Ordinary Shares | AGrant or awardAcquired | +1,937 | $0.00 | $0 | 1,937 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,883 to JPY 5,045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table II.